Hydroxychloroquine Market by Type (200mg and 400mg), Application (Rheumatoid Arthritis, Malaria, COVID-19 and Lupus)-Analysis & Forecast 2020-2030.

Report ID : 306  |  Published Date : Apr 2020  |  Pages : 150  |  Region : Global  |  Report Code : PH-21





Hydroxychloroquine Market Overview and Introduction

Hydroxychloroquine is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other applications of hydroxychloroquine include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. Recently, it has been used to treat some symptoms of the pandemic diseaseCOVID-19.

The global hydroxychloroquine market is mainly driven by growing prevalence of malaria and autoimmune diseases such as lupus and rheumatoid arthritis. Burgeoning demand of hydroxychloroquine drug worldwide for the treatment of COVID-19 is playing a pivotal role in fuelling its uptake globally. However, restrictions on its purchase ever since it has been considered for the treatment of newly discovered disease COVID-19 is likely to restrain the market growth to a certain extent.

The global Hydroxychloroquine market has been analyzed from three perspectives: Dose/Strength, Application, and Region.

Hydroxychloroquine Market by Dose/Strength

Based on dose/strength, the market has been segmented into 200mg, 400mg and others.The 400mgsegmentis expected to hold highest share during the forecast period. The segment growth can be attributed to widespread usage of 400mg hydroxychloroquine for the treatment of malaria and rheumatoid arthritis with regimen of once a week for the adults.

Hydroxychloroquine Market by Application

Based on application, the market has been segmented into rheumatoid arthritis, malaria, COVID-19, lupus and others. The COVID-19segment is expected to dominate the hydroxychloroquinemarket with highest share during the forecast period. Since it has been identified that hydroxychloroquine can be helpful in treating some symptoms of the diseaseCOVID-19 (though not proven clinically yet), pharmaceutical companies have boosted the production capacity of hydroxychloroquine drug to meet the colossal demand amid the outbreak of global pandemic COVID-19.  

Hydroxychloroquine Market by Region

Based on region, the global hydroxychloroquine market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). Asia Pacific is expected to be the fastest-growing market for hydroxychloroquine and is anticipated to contribute significantly to the global market share. The growth in this region can be attributed to the presence of prominent players and growing export demand of the drug from around the world, owing to its positive effects in the treatment of COVID-19.

Hydroxychloroquine Market Prominent Players

Some of the prominent players operating in the hydroxychloroquine market are Sanofi, Novartis AG, Ipca Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Zydus Cadila, Lupin Pharmaceuticals, Inc., DR. REDDY'S LABORATORIES LTD., Bristol Laboratories Ltd, Mylan N.V., Teva Pharmaceuticals USA, Inc., among others.